Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Ben Markman"'
Autor:
Ben Markman, Jonathan Cebon, Damien Kee, Michael Michael, Oliver Klein, Clare L. Scott, Craig Underhill, Adnan Nagrial, Louise Jackett, Jodie Palmer, Jane Yeojeong So, Matteo S. Carlino, Caroline Lum, Andreas Behren
Publikováno v:
Clinical Cancer Research. 26:4454-4459
Purpose: Combination immunotherapy with anti–CTLA-4 and anti–PD-1 blockade has demonstrated significant clinical activity across several tumor types. Neuroendocrine tumors (NET) are a heterogeneous group of rare tumors with limited treatment opti
Autor:
Eva Segelov, Amy Davies, Daphne Day, Sophia Frentzas, Cheryl-Ann Hawkins, Siddharth Menon, Ben Markman
Publikováno v:
Cancer Reports, Vol 5, Iss 2, Pp n/a-n/a (2022)
Background With the rapid influx of novel anti‐cancer agents, phase I clinical trials in oncology are evolving. Historically, response rates on early phase trials have been modest with the clinical benefit and ethics of enrolment debated. However,
Autor:
Sarina A, Piha-Paul, Kyaw Z, Thein, Paul, De Souza, Richard, Kefford, Tara, Gangadhar, Christopher, Smith, Shelly, Schuster, William C, Zamboni, Claire E, Dees, Ben, Markman
Publikováno v:
Investigational new drugs. 39(4)
Background This was a phase I/IIa study to investigate the tolerability, efficacy and pharmacokinetics (PK)/ pharmacodynamics (PD) of CRLX301, CDP-based nanoparticle formulation of docetaxel. Methods The study was conducted in two parts. In part 1, d
Autor:
Louise Jackett, Andreas Behren, Niall C. Tebbutt, Matteo S. Carlino, Jodie Palmer, Michael Michael, Jonathan Cebon, Caroline Lum, Adnan Nagrial, Craig Underhill, Ben Markman, Damien Kee, Oliver Klein
Publikováno v:
JAMA Oncol
Importance Biliary tract cancers represent a rare group of malignant conditions with very limited treatment options. Patients with advanced disease have a poor outcome with current therapies. Objective To evaluate the efficacy and safety of combinati
Autor:
Liang Liang, Kyung Hun Lee, Yee Chao, Jong Seok Lee, Chia Jui Yen, Yun Zhang, Chia-Chi Lin, Chang Hsien Lu, Michael B. Jameson, Andrew G. Hill, Ben Markman, Shahneen Sandhu, Virginia E. Paton, Michael Friedlander, John Wu, Yoon-Koo Kang, Kun Ming Rau, Ming Mo Hou, Bhumsuk Keam, Chi Yuan Wu, Jayesh Desai, Michael Millward, Lisa G. Horvath, Sanjeev Deva, Paula Barlow
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
BackgroundThe programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) axis plays a central role in suppressing antitumor immunity; axis dysregulation can be used by cancer cells to evade the immune system. Tislelizumab, an investigational
Autor:
Evangeline Samuel, Mark Shackleton, Sagun Parakh, Paul Mitchell, Gabrielle Lie, Mark Voskoboynik, Adithya Balasubramanian, Thomas John, Ben Markman, Peter Briggs, Andrew Haydon, Maggie Moore, Alison Hiong, Yeojeong So
Publikováno v:
Clinical lung cancer. 22(3)
Background The impact of radiotherapy (RT) on the efficacy and toxicity of immune checkpoint inhibitors (ICIs) in patients with metastatic non–small-cell lung cancer (NSCLC) is unclear. Materials and Methods We identified patients with metastatic N
Autor:
John Wu, Andrew G. Hill, Michael Millward, Catherine Barrow, Christopher Jackson, Michael P. Brown, William F. Patterson, Wendy Huang, Zhiyu Tang, Victoria Atkinson, Gary Richardson, Hui K Gan, Ben Tran, Yunxin Chen, Dewan Zeng, Lisa G. Horvath, Lusong Luo, Andrew Haydon, Michael B. Jameson, Lai Wang, Ben Markman, Jayesh Desai, Stephen Begbie, Phillip Parente, Adnan Nagrial, Benjamin Solomon, Michael Friedlander
Publikováno v:
Journal of Clinical Oncology
PURPOSE Lifirafenib is an investigational, reversible inhibitor of B-RAFV600E, wild-type A-RAF, B-RAF, C-RAF, and EGFR. This first-in-human, phase I, dose-escalation/dose-expansion study evaluated the safety, tolerability, and efficacy of lifirafenib
Autor:
Leonel Hernandez-Aya, Saby George, Shivaani Kummar, Leisha A. Emens, Andrew Hotson, Joshua Brody, Ben Markman, Dale R. Shepard, Daruka Mahadevan, Jonathan W. Goldman, Matthew D. Hellmann, Brian Munneke, Daniel J. Renouf, Lawrence Fong, Richard A. Miller, Lyudmyla Berim, Jason J. Luke, Mario Sznol, Amy Weise, Stephen Willingham, Ian McCaffery, Rebecca S. Heist, John D. Powderly, Toni K. Choueiri, Long Kwei, Matthew J. Riese, Po Y. Ho, Ginna G. Laport, Brian I. Rini, Jessica Hsieh, Philip Bonomi, Rachel Anne Goodwin, Brett G.M. Hughes
Publikováno v:
Cancer discovery, vol 10, iss 1
Adenosine mediates immunosuppression within the tumor microenvironment through triggering adenosine 2A receptors (A2AR) on immune cells. To determine whether this pathway could be targeted as an immunotherapy, we performed a phase I clinical trial wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d75de947792f88bb354890c23b61fe49
https://escholarship.org/uc/item/3vq7n8qs
https://escholarship.org/uc/item/3vq7n8qs
Autor:
Yuan Gao, Sheryl Koski, Timothy J. Price, Atsushi Ohtsu, John Simes, Matthew Hitron, Christopher O'Callaghan, Wei Li, Derek J. Jonker, Dongsheng Tu, Nadine M Magoski, Michael M Vickers, Sharlene Gill, Chiang J Li, Alice C. Wei, Jeremy Shapiro, John Zalcberg, Louise M. Nott, Taito Esaki, Takayuki Yoshino, Youzhi Li, Niall C. Tebbutt, Ben Markman
Publikováno v:
The Lancet Gastroenterology & Hepatology. 3:263-270
Summary Background Napabucasin is a first-in-class cancer stemness inhibitor that targets STAT3, which is a poor prognostic factor in colorectal cancer. This study aimed to test napabucasin in advanced colorectal cancer. Methods This study was a doub
Autor:
Bo Gao, Jodie Palmer, Jessica Da Gama Duarte, Richelle Linklater, Louise Jackett, Jonathan Cebon, Andreas Behren, Linda Mileshkin, Luke Quigley, Ben Markman, Matteo S. Carlino, Clare L. Scott, A. H. Strickland, Damien Kee, Oliver Klein
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
BackgroundPatients with rare cancers represent 55% of all gynecological malignancies and have poor survival outcomes due to limited treatment options. Combination immunotherapy with the anti-programmed cell death protein 1 (anti-PD-1) antibody nivolu